/ARTL
ARTL Stock - Artelo Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$1.57-7.92%
$0.14 (-7.92%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.73
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ARTL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.55 – $1.59
TARGET (TP)$1.81
STOP LOSS$1.44
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.06
52W High$28.60
52W Low$1.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-10,108,000 | $-9,930,000 | $-10,287,000 | $-7,441,000 | $-4,686,000 |
| Net Income | $-9,826,000 | $-9,289,000 | $-10,083,000 | $-7,437,000 | $-4,655,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.05 | $-3.14 | $-3.49 | $-5.97 | $-18.83 |
Company Overview
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$20
Average Target
↑ 1173.9% Upside
Now
$20
Low
$20
Average
$20
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 8th 2025 | D. Boral Capital | Upgrade | Buy | $20 |
Earnings History & Surprises
ARTLBeat Rate
39%
Last 18 quarters
Avg Surprise
-814.2%
EPS vs Estimate
Beats / Misses
7/11
Last 12 quarters
Latest EPS
$-3.97
Q4 2025
EPS Surprise History
Q1 24
-241.4%
$-5.94vs$-1.74
Q2 24
+25.7%
$-4.68vs$-6.30
Q3 24
+9.6%
$-4.50vs$-4.98
Q4 24
+14.6%
$-2.10vs$-2.46
Q1 25
-58.1%
$-7.02vs$-4.44
Q2 25
-3223.1%
$-4.32vs$-0.13
Q3 25
-33.9%
$-5.61vs$-4.19
Q4 25
-384.1%
$-3.97vs$-0.82
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.82 | $-3.97 | -384.1% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-4.19 | $-5.61 | -33.9% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.13 | $-4.32 | -3223.1% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-4.44 | $-7.02 | -58.1% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-2.46 | $-2.10 | +14.6% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-4.98 | $-4.50 | +9.6% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-6.30 | $-4.68 | +25.7% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-1.74 | $-5.94 | -241.4% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-4.20 | $-4.98 | -18.6% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.81 | $-0.56 | +30.9% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.73 | $-1.18 | -61.6% | ✗ MISS |
Q1 2023 | Mar 27, 2023 | $-0.73 | $-7.07 | -868.7% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.91 | $-0.82 | +9.9% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.85 | $-0.90 | -5.9% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-1.27 | $-0.75 | +40.9% | ✓ BEAT |
Q1 2022 | Jan 12, 2022 | $-5.40 | $-7.19 | -33.1% | ✗ MISS |
Q4 2021 | Nov 29, 2021 | $-8.99 | $-6.30 | +29.9% | ✓ BEAT |
Q3 2021 | Jul 12, 2021 | $-0.09 | $-8.99 | -9888.9% | ✗ MISS |
Latest News
ARTL stock has given up its prior gain. Artelo Biosciences shares were trading higher after the company announced the publication of a new peer-reviewed study demonstrating that intraperitoneal administration of Artelo's proprietary FABP5 inhibitor SBFI103 produces robust anxiolytic and antidepressant-like effects in a validated preclinical model of chronic stress.
➖ NeutralBenzinga•Dec 3, 2025, 02:36 PM
Artelo Biosciences shares are trading higher after the company announced the publication of a new peer-reviewed study demonstrating that intraperitoneal administration of Artelo's proprietary FABP5 inhibitor SBFI103 produces robust anxiolytic and antidepressant-like effects in a validated preclinical model of chronic stress.
📈 PositiveBenzinga•Dec 3, 2025, 01:43 PM
Artelo Biosciences Published Research Demonstrates Intraperitoneal Administration Of SBFI103 Reduces Anxiety, Depression, Increases Gene Expression
📈 PositiveBenzinga•Dec 3, 2025, 01:35 PM
Artelo Biosciences shares are trading higher after the company was granted European Patent Number EP4259111 titled "PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST"
📈 PositiveBenzinga•Dec 1, 2025, 09:26 PM
Artelo Biosciences Has Been Granted European Patent Number EP4259111 Titled "PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST"
📈 PositiveBenzinga•Dec 1, 2025, 08:58 PM
Artelo Biosciences Receives Nasdaq Delisting Notification
📉 NegativeBenzinga•Nov 25, 2025, 09:07 PM
Maxim Group Downgrades Artelo Biosciences to Hold
📉 NegativeBenzinga•Nov 19, 2025, 03:48 PM
Artelo Biosciences Q3 EPS $(3.97) Misses $(0.82) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 01:28 PM
Artelo Biosciences shares are trading lower. The company announced the publication of a peer-reviewed article, "The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers", in Drug Discovery Today.
📉 NegativeBenzinga•Nov 4, 2025, 02:27 PM
Artelo Biosciences Announces Publication Of Peer-Reviewed Article, "The Emerging Role Of Fatty Acid Binding Protein 3 (FABP3) In Cancers", In Drug Discovery Today
📈 PositiveBenzinga•Nov 4, 2025, 01:34 PM
Artelo Biosciences Appoints Mark Spring CFO, Effective Nov. 1
➖ NeutralBenzinga•Oct 27, 2025, 12:01 PM
Artelo Biosciences Reports Phase 1 And 2 Data For ART26.12 And ART27.13, Highlighting Safety And Significant Weight Gain In Cancer Anorexia Trial
📈 PositiveBenzinga•Oct 15, 2025, 01:18 PM
Artelo Biosciences Prices $2.0M Public Offering
➖ NeutralBenzinga•Sep 30, 2025, 02:11 PM
Artelo Biosciences prices $2 million public offering; shares down over 24%
📉 NegativeSeeking Alpha•Sep 30, 2025, 01:08 PM
Reported Earlier, Artelo Biosciences Commences Underwritten Public Offering Of Common Stock And Pre Funded Warrants
📉 NegativeBenzinga•Sep 30, 2025, 06:34 AM
Artelo Biosciences Announces Publication Of New Preclinical Data On ART12.11, Proprietary Cannabidiol:tetramethylpyrazine Cocrystal
📈 PositiveBenzinga•Sep 10, 2025, 12:36 PM•Also:
D. Boral Capital Downgrades Artelo Biosciences to Hold
📉 NegativeBenzinga•Sep 8, 2025, 11:21 AM
Artelo Biosciences announces pricing of $3 million public offering
➖ NeutralSeeking Alpha•Sep 4, 2025, 12:47 PM
Artelo Biosciences Prices 640,924 Share Offering At $4.40/Share And Pre-Funded Warrants At $4.399; Proceeds $3M
➖ NeutralBenzinga•Sep 4, 2025, 12:40 PM
Artelo Biosciences shares are trading lower after the company announced a proposed underwritten public offering of common stock and/or pre-funded warrants.
📉 NegativeBenzinga•Sep 4, 2025, 11:56 AM
Frequently Asked Questions about ARTL
What is ARTL's current stock price?
Artelo Biosciences, Inc. (ARTL) is currently trading at $1.57 per share. The stock has moved -7.92% today.
What is the analyst price target for ARTL?
No analyst price targets are currently available for this stock.
What sector is Artelo Biosciences, Inc. in?
Artelo Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ARTL's market cap?
Artelo Biosciences, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ARTL pay dividends?
No, Artelo Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCARM
Carisma Therapeutics, Inc.
$0.05
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
PTIX
Protagenic Therapeutics, Inc.
$1.19
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
SPRC
SciSparc Ltd.
$1.46
Mkt Cap: $0.0B
WINT
Windtree Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
Explore stocks similar to ARTL for comparison